Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

Tenax Therapeutics, Inc. today announced Dr. Sanjiv Shah will present data and review the scientific basis for the use of levosimendan in PH-HFpEF.

Tenax Therapeutics, Inc. announced that the United States Patent and Trademark Office has granted the Company a patent covering the use of TNX-103, TNX-102, TNX-101, the active metabolites of levosimendan and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients.

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.

Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.

Tenax Therapeutics, Inc. today announced that Stuart Rich, Tenax CMO, will moderate ”LEVEL Setting,” a scientific round-table exploration of the rationale for TNX-103 (oral levosimendan), for the treatment of PH-HFpEF.

Tenax Therapeutics, Inc. today announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).